Company Overview of Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. develops products to ameliorate the cause and symptoms associated with urological ailments. Its products include URG101, a proprietary combination therapy product that has completed a Phase II double blinded, placebo controlled, and multi-center trial for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS); and URG501, an oral pentosan polysulfate sodium therapy, which is in pre-clinical stage for the treatment of IC/BPS. The company is based in North Brunswick, New Jersey.
Technology Center of New Jersey
675 Highway One B-206
North Brunswick, NJ 08902
Key Executives for Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Health-Right Discoveries, Inc.||United States|
|Cystic Fibrosis Foundation Therapeutics Inc.||United States|
|Gorbec Pharmaceutical Services Inc.||United States|
|OncoPep, Inc.||United States|
|Tower Holdings, Inc.||United States|
Recent Private Companies Transactions
July 1, 2015
To contact Urigen Pharmaceuticals, Inc., please visit www.urigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.